See the latest Coronavirus Information including testing sites, visitation restrictions, appointments and scheduling, and more.
There is no publicly available rating for this medical professional for one of the following reasons:
Adults (18-65), Geriatrics (65+)
Adults (18-65), Geriatrics (65+)
Research Interests Our goal is to develop a better understanding of HIV-1 immunopathogenesis and new immune-based strategies of anti-HIV therapy that are better tolerated and more sustainable for patient populations than the life-long use of antiretroviral therapy.Research DescriptionIntroductionThe Montaner laboratory is investigating mechanisms of disease in HIV-1 infection and novel approaches to augment immune function by combining virological and immune-based research on patient-derived material as well as by using laboratory models of virus infection. The work is focused on 1) regulation of innate immunity, 2) identifying new mechanisms of immunodeficiency and discovering new approaches to reverse them, 3) exploring new therapy management practices, and 4) understanding the relationship between immune antiviral responses and control of HIV-1 infection.Current Research Activities and InterestsInnate Immunity & HIV-1 Infection: Dendritic cells & Natural Killer Cells Direct or indirect interactions of viral particles with innate and specific adaptive immunity effector cells affects the cross talk between antigen presenting cells (APCs), NK cells and the antigen specific T and B-lymphocytes, and may contribute to regulate HIV disease progression. Specifically, we are pursuing analysis of the effects of HIV infection in macrophages, dendritic cells and Natural Killer cells.A relationship between levels of HIV replication and innate cell function is supported by our preliminary data on DC and NK subset changes and viral replication in HIV-infected individuals showing an impairment of NK cell responses, APC endocytic uptake, differential expression of cell surface molecules associated with APC function, increased APC apoptosis, decreased IL-12 secretion, decreased IFN-? secretion and a loss of plasmacytoid dendritic cells (PDCs) and myeloid dendritic cells (MDCs) in PBMC. Based on these observations and the observed effects of antiretroviral therapy on DC and NK cell subsets, the inverse correlation between viral load and DC subsets in untreated HIV positive subjects and our observations of augmented NK lytic activity by activated DC, we are addressing longitudinal analysis and mechanistic experiments on DC/HIV interactions to test the hypothesis that HAART-mediated viral suppression restores mature NK and DC subsets necessary to activate innate mechanisms of antiviral control through lysis of infected cells. The long-term goal of this area of focus is to define the contribution of two major components of the innate immune system (accessory and Natural Killer cells) in controlling HIV replication thereby modifying disease progression. The short-term goal of our effort is to address the consequences of immune reconstitution on innate immunity following antiretroviral therapy, with particular emphasis on correlates of DC and NK cell functions and the consequences of HIV interactions with DC subsets. While adaptive HIV-specific immune responses continue to be an area of active investigation in AIDS research, the potential contribution of innate immune response, such as the relationship between DC subsets, disease progression and its consequences on other innate functions such as NK function remains largely unexplored in HAART settings. This study represents a hypothesis-driven collaborative effort by The Wistar Institute, the Infectious Disease Division of the University of Pennsylvania Hospital, Philadelphia FIGHT, Schering-Plough, Becton Dickinson, The Women's Interagency Study Cohort and the Multiple AIDS Cohort Study (MACS).
Cai Y, Watkins MA, Xue F, Ai Y, Cheng H, Midkiff CC, Wang X, Alvarez X, Poli ANR, Salvino JM, Veazey RS, Montaner LJ: BCL6 BTB-specific inhibition via FX1 treatment reduces Tfh cells and reverses lymphoid follicle hyperplasia in Indian rhesus macaque (Macaca mulatta) J Med Primatol 49 (1): 26-33,2020.
Giron LB, Papasavvas E, Azzoni L, Yin X, Anzurez A, Damra M, Mounzer K, Kostman JR, Sanne I, Firnhaber CS, Tateno H, Liu Q, Montaner LJ, Abdel-Mohsen M: Plasma and antibody glycomic biomarkers of time to HIV rebound and viral setpoint AIDS : Epub ahead of print,2020.
Yadav A, Kossenkov AV, Knecht VR, Showe LC, Ratcliffe SJ, Montaner LJ, Tebas P, Collman RG: Evidence for Persistent Monocyte and Immune Dysregulation After Prolonged Viral Suppression Despite Normalization of Monocyte Subsets, sCD14 and sCD163 in HIV-Infected Individuals Patho Immun 4 (2): 324-362,2019.
Abdulhaqq SA, Martinez M, Kang G, Rodriguez IV, Nichols SM, Beaumont D, Joseph J, Azzoni L, Yin X, Wise M, Weiner D, Liu Q, Foulkes A, Münch J, Kirchhoff F, Coutifaris C, Tomaras GD, Sariol C, Marx PA, Li Q, Kraiselburd EN, Montaner LJ: Repeated semen exposure decreases cervicovaginal SIVmac251 infection in rhesus macaques Nat Commun 10 (1): 3753,2019.
Papasavvas E, Azzoni L, Kossenkov AV, Dawany N, Morales KH, Fair M, Ross BN, Lynn K, Mackiewicz A, Mounzer K, Tebas P, Jacobson JM, Kostman JR, Showe L, Montaner LJ: NK Response Correlates with HIV Decrease in Pegylated IFN-α2a-Treated Antiretroviral Therapy-Suppressed Subjects J Immunol 203 (3): 705-717,2019.
Perales-Puchalt A, Duperret EK, Yang X, Hernandez P, Wojtak K, Zhu X, Jung S-H, Tello-Ruiz E, Wise MC, Montaner LJ, Muthumani K, Weiner DB: DNA-encoded bispecific T cell engagers and antibodies present long-term antitumor activity JCI Insight 4 (8): 2019.
Papasavvas E, Kossenkov AV, Azzoni L, Zetola NM, Mackiewicz A, Ross BN, Fair M, Vadrevu S, Ramogola-Masire D, Sanne I, Firnhaber C, Montaner LJ: Gene expression profiling informs HPV cervical histopathology but not recurrence/relapse after LEEP in ART-suppressed HIV+HPV+ women Carcinogenesis 40 (2): 225-233,2019.
Julg B, Dee L, Ananworanich J, Barouch DH, Bar K, Caskey M, Colby DJ, Dawson L, Dong KL, Dubé K, Eron J, Frater J, Gandhi RT, Geleziunas R, Goulder P, Hanna GJ, Jefferys R, Johnston R, Kuritzkes D, Li JZ, Likhitwonnawut U, van Lunzen J, Martinez-Picado J, Miller V, Montaner LJ, Nixon DF, Palm D, Pantaleo G, Peay H, Persaud D, Salzwedel J, Salzwedel K, Schacker T, Sheikh V, Søgaard Ole S, Spudich S, Stephenson K, Sugarman J, Taylor J, Tebas P, Tiemessen CT, Tressler R, Weiss CD, Zheng L, Robb ML, Michael NL, Mellors JW, Deeks SG, Walker BD: Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting Lancet HIV 6 (4): e259-e268,2019.
Perales-Puchalt A, Wojtak K, Duperret EK, Yang X, Slager AM, Yan J, Muthumani K, Montaner LJ, Weiner DB: Engineered DNA Vaccination against Follicle-Stimulating Hormone Receptor Delays Ovarian Cancer Progression in Animal Models Mol Ther 27 (2): 314-325,2019.
Colomb F, Giron LB, Premeaux TA, Mitchell BI, Niki T, Papasavvas E, Montaner LJ, Ndhlovu LC, Abdel-Mohsen M: Galectin-9 Mediates HIV Transcription by Inducing TCR-Dependent ERK Signaling Front Immunol 10 : 267,2019.
The Wistar Institute 3601 Spruce Street